Asian-Australasian Journal of Animal Sciences

Asian Australasian Association of Animal Production Societies (아세아태평양축산학회)
권호 표지
DOI QR코드

DOI QR Code

Therapy of Diabetes Mellitus Using Experimental Animal Models

  • Min, T.S. (National Research Foundation of Korea) ;
  • Park, Soo Hyun (National Research Foundation of Korea)
  • Received : 2009.12.24
  • Accepted : 2010.01.29
  • Published : 2010.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Diabetes mellitus is a worldwide epidemic with high mortality. As concern over this disease rises, the number and value of research grants awarded by the National Research Foundation of Korea (NRF) have increased. Diabetes mellitus is classified into two groups. Type 1 diabetes requires insulin treatment, whereas type 2 diabetes, which is characterized by insulin resistance, can be treated using a variety of therapeutic approaches. Hyperglycemia is thought to be a primary factor in the onset of diabetes, although hyperlipidemia also plays a role. The major organs active in the regulation of blood glucose are the pancreas, liver, skeletal muscle, adipose tissue, intestine, and kidney. Diabetic complications are generally classified as macrovascular (e.g., stroke and heart disease) or microvascular (i.e., diabetic neuropathy, nephropathy, and retinopathy). Several animal models of diabetes have been used to develop oral therapeutic agents, including sulfonylureas, biguanides, thiazolidinediones, acarbose, and miglitol, for both type 1 and type 2 diseases. This review provides an overview of diabetes mellitus, describes oral therapeutic agents for diabetes and their targets, and discusses new developments in diabetic drug research.

Keywords

References

  1. Adeghate, E., P. Schattner and E. Dunn. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann. NY. Acad. Sci. 1084:1-29 https://doi.org/10.1196/annals.1372.029
  2. Asano, T., M. Fujishiro, A. Kushiyama, Y. Nakatsu, M. Yoneda, H. Kamata and H. Sakoda. 2007. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol. Pharm. Bull. 30:1610-1616 https://doi.org/10.1248/bpb.30.1610
  3. Ashcroft, F. M. and P. Rorsman. 1990. ATP-sensitive K+ channels: a link between B-cell metabolism and insulin secretion. Biochem. Soc. Trans. 18:109-111
  4. Basit, A., M. Z. Hydrie, R. Hakeem, M. Y. Ahmedani and Q. Masood. 2004. Frequency of chronic complications of type II diabetes. J. Coll. Physicians Surg. Pak. 14:79-83
  5. Bjornholm, M. and J. R. Zierath. 2005. Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes. Biochem. Soc. Trans. 33:354-357 https://doi.org/10.1042/BST0330354
  6. Bluher, M. 2009. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes. 117:241-250 https://doi.org/10.1055/s-0029-1192044
  7. Bonner-Weir, S., D. F. Trent, R. N. Honey and G. C. Weir. 1981. Responses of neonatal rat islets to streptozotocin: Limited Bcell regeneration and hyperglycemia. Diabetes 30:64-69 https://doi.org/10.2337/diabetes.30.1.64
  8. Budhiraja, S. and J. Singh. 2008. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam. Clin. Pharmacol. 22:231-240 https://doi.org/10.1111/j.1472-8206.2008.00583.x
  9. Capeau, J. 2008. Insulin resistance and steatosis in humans. Diabetes. Metab. 34:649-657 https://doi.org/10.1016/S1262-3636(08)74600-7
  10. Chiasson, J. L., R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik and M. Laakso. 2002. STOP-NIDDM Trail Research Group. 2002. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077 https://doi.org/10.1016/S0140-6736(02)08905-5
  11. Christensen, M., F. K. Knop, J. J. Holst and T. Vilsboll. 2009. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 12:503-513
  12. Cleasby, M. E., N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen and J. M. Ye. 2004. Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes53:3258-3266 https://doi.org/10.2337/diabetes.53.12.3258
  13. Crawford, T. N., D. V. Alfaro 3rd, J. B. Kerrison and E. P. Jablon. 2009. Diabetic retinopathy and angiogenesis. Curr. Diabetes Rev. 5:8-13 https://doi.org/10.2174/157339909787314149
  14. Dahan, A. and S. G. McAfee. 2009. A proposed role for the psychiatrist in the treatment of adolescents with type I diabetes. Psychiatr. Q. 80:75-85 https://doi.org/10.1007/s11126-009-9099-1
  15. Daneman, D. 2009. State of the world's children with diabetes. Pediatr Diabetes 10:120-126 https://doi.org/10.1111/j.1399-5448.2008.00479.x
  16. Davies, M. J. 2002. Insulin secretagogues. Curr. Med. Res. Opin. 18:s22-s30 https://doi.org/10.1185/030079902125000200
  17. Del, P. S., C. Bianchi and P. Marchetti. 2007. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab. Res. Rev. 23:518-527 https://doi.org/10.1002/dmrr.770
  18. Diabetes Prevention Program Research Group. 2005. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 28:138-144 https://doi.org/10.2337/diacare.28.1.138
  19. Ding, S. Y., Z. F. Shen, Y. T. Chen, S. J. Sun, Q. Liu and M. Z. Xie. 2005. Pioglitazone can ameliorate insulin resistance in lowdose streptozotocin and high sucrose-fat diet induced obese rats. Acta. Pharmacol. Sin. 26:575-580 https://doi.org/10.1111/j.1745-7254.2005.00090.x
  20. Dubuc, P. U. 1976. The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25:1567-1574 https://doi.org/10.1016/0026-0495(76)90109-8
  21. Edelman, S. V. 1998. Type II diabetes mellitus. Adv. Intern. Med. 43:449-500
  22. Elnasri, H. A. and A. M. Ahmed. 2008. Patterns of lipid changes among type 2 diabetes patients in Sudan. East Mediterr. Health J. 14:314-324
  23. Fallucca, F. and P. Pozzilli. 2009. Physical exercise, public health and quality of life in diabetes. Diabetes Metab. Res. Rev. 25:S1-S3 https://doi.org/10.1002/dmrr.990
  24. Fawcett, J. and R. Rabkin. 1993. Degradation of insulin by isolated rat renal cortical endosomes. Endocrinology 133:1539-1547 https://doi.org/10.1210/en.133.4.1539
  25. Federico, L. M., M. Naples, D. Taylor and K. Adeli. 2006. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-relatedkinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 55:1316-1326 https://doi.org/10.2337/db04-1084
  26. Frojdo, S., H. Vidal and L. Pirola. 2009. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim. Biophys. Acta. 1792:83-92 https://doi.org/10.1016/j.bbadis.2008.10.019
  27. Fuentes, B., J. Castillo, B. San Jose, R. Leira, J. Serena, J Vivancos, A. D$\acute{a}$valos, A. G. Nu$\tilde{n}$ez, J. Egido and E. Díez-Tejedor. 2009. The prognostic value of capillary glucose levels in acute stroke. The GLycemia in Acute Stroke (GLIAS) Study. Stroke. 40:562-568 https://doi.org/10.1161/STROKEAHA.108.519926
  28. Gallwitz, B. 2008. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs. 11:906-917
  29. Haffner, S. M., A. S. Greenberg, W. M. Weston, H. Chen, K. Williams and M. I. Freed. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-884 https://doi.org/10.1161/01.CIR.0000025403.20953.23
  30. Hallakou, S., L. Doar$\acute{e}$, F. Foufelle, M. Kergoat, M. Guerre-Millo, M. F. Berthault, I. Dugail, J. Morin, J. Auwerx and P. Ferré. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399 https://doi.org/10.2337/diabetes.46.9.1393
  31. Hyvorinen, M., Q. Qiao, J. Tuomilehto, T. Laatikainen, R. J. Heine, C. D. Stehouwer, K. G. Alberti, K. Pyorol, B. Zethelius and B. Stegmayr 2009. DECODE Study Group. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care 32:348-354 https://doi.org/10.2337/dc08-1411
  32. Ito, M., Y. Kondo, A. Nakatani, K. Hayashi and A. Naruse. 2001. Characterization of low dose streptozotocin-induced progressive diabetes in mice. Environ. Toxicol. Pharmacol. 9:71-78 https://doi.org/10.1016/S1382-6689(00)00064-8
  33. Joshi, S. R. 2003. Metabolic syndrome-emerging clusters of the Indian phenotype. J. Assoc. Physicians India 51:445-446
  34. Junod, A., A. E. Lambert, W. Stauffacher and A. E. Renold. 1967. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 126:201-205
  35. Kahn, S. E., S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. Oneil, B. Zinman and G. Viberti. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355:2427-2443 https://doi.org/10.1056/NEJMoa066224
  36. Kanwar, Y. S., J. Wada, L. Sun, P. Xie, E. I. Wallner, S. Chen, S. Chugh and F. R. Danesh. 2008. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood). 233:4-11 https://doi.org/10.3181/0705-MR-134
  37. Katsuno, K., Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura and M. Isaji. 2007. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol.Exp. Ther. 320:323-330 https://doi.org/10.1124/jpet.106.110296
  38. Kawano, K., T. Hirashima, S. Mori, Y. Saitoh, M. Kurosumi and T. Natori. 1992. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422-1428 https://doi.org/10.2337/diabetes.41.11.1422
  39. Khan, A. H. and J. E. Pessin. 2002. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45:1475-1483 https://doi.org/10.1007/s00125-002-0974-7
  40. Kim, J. H., P. M. Nishina and J. K. Naggert 1998. Genetic models for non insulin dependent diabetes mellitus in rodents. J. Basic Clin. Physiol. Pharmacol. 9:325-345 https://doi.org/10.1515/JBCPP.1998.9.2-4.325
  41. Klover, P. J. and R. A. Mooney. 2004. Hepatocytes: critical for glucose homeostasis. Int. J. Biochem. Cell Biol. 36:753-758 https://doi.org/10.1016/j.biocel.2003.10.002
  42. Lafontan, M., P. V. Piazza and J. Girard. 2007. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab. 33:85-95 https://doi.org/10.1016/j.diabet.2007.02.001
  43. Lanner, J. T., J. D. Bruton, A. Katz and H. Westerblad. 2008. $Ca^{2+}$ and insulin-mediated glucose uptake. Curr. Opin. Pharmacol. 8:339-345 https://doi.org/10.1016/j.coph.2008.01.006
  44. Lencioni, C., R. Lupi and S. Del Prato. 2008. Beta-cell failure in type 2 diabetes mellitus. Curr. Diab. Rep. 8:179-184 https://doi.org/10.1007/s11892-008-0031-0
  45. Makino, S., K. Kunimoto, Y. Munaoko, Y. Mizushima, K. Katagiri and Y. Tochino. 1980. Breeding of a non-obese diabetic strain of mice. Exp. Anim. 29:1-13
  46. Mellor, K. M., R. H. Ritchie and L. M. Delbridge. 2010. Reactive oxygen species and insulin resistant cardiomyopathy. Clin. Exp. Pharmacol. Physiol. (in press)
  47. Moore, K. R., T. S. Harwell, J. M. McDowall, S. D. Helgerson, and D. Gohdes. 2003. Three-year prevalence and incidence of diabetes among American Indian youth in Montana and Wyoming, 1999 to 2001. J. Pediatr. 143:368-371 https://doi.org/10.1067/S0022-3476(03)00295-6
  48. Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell and L. J. Goodyear. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081 https://doi.org/10.2337/diabetes.51.7.2074
  49. Nakasone, H., S. Kako, H. Endo, A. Ito, M. Sato, K. Terasako, S. Okuda, Y. Tanaka, R. Yamazaki, K. Oshima, A. Tanihara, M. Kida, T. Higuchi, K. Izutsu, J. Nishida, A. Urabe, K. Usuki, and Y. Kanda. 2009. Diabetes mellitus is associated with high early-mortality and poor prognosis in patients withautoimmune hemolytic anemia. Hematology 14:361-365 https://doi.org/10.1179/102453309X12473408860262
  50. Nakamura, T., T. Funahashi, S. Yamashita, M. Nishida, Y. Nishida,M. Takahashi, K. Hotta, H. Kuriyama, S. Kihara, N. Ohuchi, T. Nishimura, B. I. Kishino, K. Ishikawa, T. Kawamoto, K. Tokunaga, C. Nakagawa, I. Mineo, F. Watanabe, S. Tarui and Y. Matsuzawa. 2001. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceralfat accumulation--double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. 54:181-190 https://doi.org/10.1016/S0168-8227(01)00319-9
  51. Nakhooda, A. F., A. A. Like, C. I. Chappel, F. T. Murray and E. B. Marliss. 1977. The spontaneously diabetic wistar rat. Metabolic and morphological studies. Diabetes 26:100-112 https://doi.org/10.2337/diabetes.26.2.100
  52. Neeli, H., R. Gadi and D. J. Rader. 2009. Managing diabetic dyslipidemia: beyond statin therapy. Curr. Diab. Rep. 9:11-17 https://doi.org/10.1007/s11892-009-0004-y
  53. Nissen, S. E. and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356:2457-2471 https://doi.org/10.1056/NEJMoa072761
  54. Nolan, C. J. and M. Prentki. 2008. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol. Metab. 19:285-291 https://doi.org/10.1016/j.tem.2008.07.006
  55. O'Moore-Sullivan, T. M. and J. B. Prins. 2002. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med. J. Aust. 176:381-386
  56. Olsen, W. A. and I. H. Rosenberg. 1970. Intestinal transport of sugar and amino acids in diabetic rats. J. Clin. Invest. 49:96-105 https://doi.org/10.1172/JCI106227
  57. Phielix, E. and M. Mensink. 2008. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol. Behav. 94:252-258 https://doi.org/10.1016/j.physbeh.2008.01.020
  58. Prentki, M. 1996. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur. J. Endocrinol. 134:272-286 https://doi.org/10.1530/eje.0.1340272
  59. Purnell, J. Q. and C. Weyer. 2003. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol. 2:33-47 https://doi.org/10.2165/00024677-200302010-00004
  60. Qi, L., F. B. Hu and G. Hu. 2008. Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr. Mol. Med. 8:519-532 https://doi.org/10.2174/156652408785747915
  61. Qin, B., W. Qiu, R. K. Avramoglu and K. Adeli. 2007. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 56:450-461 https://doi.org/10.2337/db06-0518
  62. Ramachandran, A., R. C. Wan Ma and C. Snehalatha. 2010. Diabetes in Asia. Lancet. (in press)
  63. Reddi, A. S. and R. A. Camerini-Davalos. 1988. Hereditary diabetes in the KK mouse: an overview. Adv. Exp. Med. Biol. 246:7-15
  64. Rerup, C. C. 1970. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol. Rev. 22:485-518
  65. Retnakaran, R. and B. Zinman. 2009. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 373:2088-2090 https://doi.org/10.1016/S0140-6736(09)61029-1
  66. Raddatz, D. and G. Ramadori. 2007. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z. Gastroenterol. 45:51-62 https://doi.org/10.1055/s-2006-927394
  67. Roden, M., K. F. Petersen and G. I. Shulman. 2001. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog. Horm. Res. 56:219-237 https://doi.org/10.1210/rp.56.1.219
  68. Rodriguez, B. L., R. D'Agostino, R. D. Abbott, A. Kagan, C. M. Burchfiel, K. Yano, G. W. Ross, H. Silbershatz, M. W. Higgins, J. Popper, P. A. Wolf and J. D. Curb. 2002. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factoreffects. Stroke 33:230-236 https://doi.org/10.1161/hs0102.101081
  69. Ron, Y., J. Wainstein, A. Leibovitz, N. Monastirsky, B. Habot, Y. Avni and R. Segal. 2002. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J. Gerontol. A. Biol. Sci. Med. Sci. 57:M111-M114 https://doi.org/10.1093/gerona/57.2.M111
  70. Sacks, D. B. and J. M. McDonald. 1996. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am. J. Clin. Pathol. 105:149-156
  71. Salman, S., F. Salman, I. Satman, Y. Yilmaz, E. Ozer, A. Sengul, H. O. Demirel, K. Karoidao, N. Dinoao and M. T. Yilmaz. 2001. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr. Med. Res. Opin. 16:296-306 https://doi.org/10.1185/030079901750120231
  72. Sander, G. E., F. E. Wilklow and T. D. Giles. 2004. Heart failure in diabetes mellitus: causal and treatment considerations. Minerva Cardioangiol. 52:491-503
  73. Shafrir, E. 1992. Animal models of non insulin dependent diabetes. Diabetes Metab. Rev. 8:179-208 https://doi.org/10.1002/dmr.5610080302
  74. Sicree, R., J. Shaw and P. Zimmet. 2006. Prevalence and projections. In: Diabetes atlas (Ed. D. Gan), 3rd edn. Brussels: International Diabetes Federation, 16-104
  75. Silva, K. C., M. A. Rosales, S. K. Biswas, J. B. Lopes de Faria andJ. M. Lopes de Faria. 2009. Diabetic retinal neurodegeneration improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 58:1382-1390 https://doi.org/10.2337/db09-0166
  76. Singh, S., Y. K. Loke and C. D. Furberg. 2007. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30:2148-2153 https://doi.org/10.2337/dc07-0141
  77. Soldatos, G. and M. E. Cooper. 2008. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res. Clin. Pract. 82:S75-S79 https://doi.org/10.1016/j.diabres.2008.09.042
  78. Sowers, J. R. 2008. Endocrine functions of adipose tissue: focus on adiponectin. Clin. Cornerstone 9:32-38 https://doi.org/10.1016/S1098-3597(08)60026-5
  79. Srinivasan, K., B. Viswanad, L. Asrat, C. L. Kaul and P. Ramarao. 2005. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52:313-320 https://doi.org/10.1016/j.phrs.2005.05.004
  80. Stefansson, E., T. Bek, M. Porta, N. Larsen, J. K. Kristinsson and E. Agardh. 2000. Screening and prevention of diabetic blindness. Acta. Ophthalmol. Scand. 78:374-385 https://doi.org/10.1034/j.1600-0420.2000.078004374.x
  81. Tan, J. T., L. S. Tan, K. S. Chia, S. K. Chew and E. S. Tai. 2008. A family history of type 2 diabetes is associated with glucose intolerance and obesity-related traits with evidence of excess maternal transmission for obesity-related traits in a South East Asian population. Diabetes Res. Clin. Pract. 82:268-275 https://doi.org/10.1016/j.diabres.2008.08.005
  82. Taplin, C. E. and J. M. Barker. 2008. Autoantibodies in type 1 diabetes. Autoimmunity 41:11-18 https://doi.org/10.1080/08916930701619169
  83. Taylor, C. and F. D. Hobbs. 2009. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Br. J. Gen. Pract. 59:520-524 https://doi.org/10.3399/bjgp09X453440
  84. Therond, P. 2009. Catabolism of lipoproteins and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care. 12:366-371 https://doi.org/10.1097/MCO.0b013e32832c5a12
  85. Thorens, B. 2001. GLUT2 in pancreatic and extra-pancreatic gluco-detection (review). Mol. Membr. Biol. 18:265-273 https://doi.org/10.1080/09687680110100995
  86. Tomkin, G. H. 2008. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler. Suppl. 9:27-32 https://doi.org/10.1016/j.atherosclerosissup.2008.05.012
  87. Tuomilehto, J., D. Rastenyte, P. Jousilahti, C. Sarti and E. Vartiainen. 1996. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 27:210-215 https://doi.org/10.1161/01.STR.27.2.210
  88. Turcotte, L. P. and J. S. Fisher. 2008. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys. Ther. 88:1279-1296 https://doi.org/10.2522/ptj.20080018
  89. Unger, R. H. and Y. T. Zhou. 2001. Lipotoxicity of beta-cells in obesity and in other cause of fatty acid spillover. Diabetes 1:S118- S121
  90. Valverde, A. M., D. J. Burks, I. Fabregat, T. L. Fisher, J. Carretero, M. F. White and M. Benito. 2003. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 52:2239-2248 https://doi.org/10.2337/diabetes.52.9.2239
  91. Van Gaal, L., F. Nobels and I. De Leeuw. 1991. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z. Gastroenterol. 29:642-644
  92. Weltman, N. Y., S. A. Saliba, E. J. Barrett and A. Weltman. 2009. The use of exercise in the management of type 1 and type 2 diabetes. Clin. Sports Med. 28:423-439 https://doi.org/10.1016/j.csm.2009.02.006
  93. Wolf, P. A., R. B. D'Agostino, A. J. Belanger and W. B. Kannel. 1991. Probability of stroke: a risk profile from the Framingham Study. Stroke. 22:312-318 https://doi.org/10.1161/01.STR.22.3.312
  94. Yamamoto, H., Y. Uchigata and H. Okamoto. 1981. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthatase in pancreatic islets. Nature 294:284-286 https://doi.org/10.1038/294284a0
  95. Yamauchi, T., J. Kamon, H. Waki, K. Murakami, K. Motojima, K. Komeda, T. Ide, N. Kubota, Y. Terauchi, K. Tobe, H. Miki, A. Tsuchida, Y. Akanuma, R. Nagai, S. Kimura and T. Kadowaki. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:41245-41254 https://doi.org/10.1074/jbc.M103241200
  96. Ye, Y. L., Z. Zhou, H. J. Zou, Y. Shen, T. F. Xu, J. Tang, H. Z. Yin, M. L. Chen, Y. Leng and J. H. H. Shen. 2009. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg. Med. Chem. 17:5722-5732 https://doi.org/10.1016/j.bmc.2009.05.082
  97. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174 https://doi.org/10.1172/JCI13505
  98. Zierath, J. R., A. Krook and H. Wallberg-Henriksson. 2000. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821-835 https://doi.org/10.1007/s001250051457
  99. Zucker, L. M. and H. N. Antoniades. 1972. Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology 90:1320-1330 https://doi.org/10.1210/endo-90-5-1320
  100. Zucker, T. F. and L. M. Zucker. 1962. Hereditary obesity in the rat associated with high serum fat and cholesterol. Proc. Soc. Exp. Biol. Med. 110:165-171

Cited by

  1. Antihyperglycemic Studies on the Leaf Extract and Active Fractions of <i>Newbouldia laevis</i> (Bignoniaceae) vol.06, pp.11, 2015, https://doi.org/10.4236/pp.2015.611054